Ras/Raf signalling and emerging pharmacotherapeutic targets (Q34660771)

3 August 2017

1 reference

title

Ras/Raf signalling and emerging pharmacotherapeutic targets (English)

1 reference

3 August 2017

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

709-718

1 reference

RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Regulation of Raf-1 activation and signalling by dephosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Cooperating oncogenes converge to regulate cyclin/cdk complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

MEK kinase activity is not necessary for Raf-1 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Prevention of vasospasm in penetrating arteries with MAPK inhibitors in dog double-hemorrhage model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Blocking oncogenic Ras signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Farnesyltransferase inhibitors: mechanism and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Current status of clinical trials of farnesyltransferase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Antisense therapeutics: lessons from early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

The many faces of Ras: recognition of small GTP-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Sulindac sulfide inhibits Ras signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

New indene-derivatives with anti-proliferative properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Synthesis and biological evaluation of cycloalkylidene carboxylic acids as novel effectors of Ras/Raf interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Selection of phage-displayed fab antibodies on the active conformation of ras yields a high affinity conformation-specific antibody preventing the binding of c-Raf kinase to Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Reovirus oncolysis of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Viruses as therapeutic agents against malignant disease of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Paradoxical activation of Raf by a novel Raf inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Selective GRB2 SH2 inhibitors as anti-Ras therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.6.709

Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.52.1086

Identifiers

DOI

10.1517/14656566.3.6.709

1 reference

3 August 2017

1 reference